The Vaping Longitudinal Data: What 15 Years of Evidence Actually Shows
We now have a decade and a half of population-level data on vaping. The fears that animated the early debate—gateway effects, renormalization, youth epidemics—have not materialized as predicted. The benefits have materialized more strongly than expected. The evidence is in. Is anyone listening?
In 2007, the first e-cigarette entered the European market. In 2024, we have seventeen years of population-level data across dozens of countries. **We now know more about the real-world effects of vaping than we knew about the real-world effects of most pharmaceutical products at the time of their approval.** The data is not perfect—no population-level data ever is—but it is extensive, consistent, and increasingly difficult to dismiss. The question is no longer 'what does the evidence suggest?' The question is 'why is policy not following the evidence?'
**The gateway hypothesis—that vaping leads nonsmoking youth to cigarette smoking—has not been supported at the population level.** The countries with the highest youth vaping rates (the UK, New Zealand) have the fastest-declining youth smoking rates. The countries that restricted vaping most aggressively (Australia, which requires a prescription for nicotine vaping products) have seen slower declines in smoking. The temporal association at the population level is the opposite of what the gateway hypothesis predicts: more vaping is associated with less smoking, not more. Individual-level studies that find an association between youth vaping and subsequent smoking are almost certainly confounded by shared risk factors—the same adolescents who are at risk for vaping are at risk for smoking. **The gateway hypothesis, which dominated the youth-vaping discourse for years, has been refuted at the population level. The policy implications of that refutation have not yet been absorbed.**
**The cessation evidence is stronger than skeptics acknowledge.** Randomized controlled trials have demonstrated that vaping is more effective than NRT for smoking cessation—the 2019 Hajek trial in the New England Journal of Medicine found an 18% one-year abstinence rate for vaping versus 10% for NRT. Population-level studies have found that smokers who vape are more likely to quit than smokers who don't—and that the effect is stronger in countries that have embraced vaping as a harm reduction tool (the UK) than in countries that have restricted it (Australia). The real-world evidence—the rapid decline in smoking prevalence in the UK, New Zealand, Sweden, and Japan (where heated tobacco, not vaping, played the substitution role) following the introduction of reduced-risk products—is consistent with a causal effect of vaping on smoking cessation at the population level. **The evidence that vaping helps smokers quit is as strong as the evidence for any smoking cessation intervention. The institutions that continue to describe the evidence as 'inconclusive' are not following the science. They are following their institutional interests.**
**The long-term health effects remain the most important unknown.** We do not have 30-year epidemiological data on vaping because vaping has not existed for 30 years. The data we do have—15-year follow-up studies, biomarker studies, short-term clinical studies, and mechanistic toxicology—consistently indicates that vaping is substantially less harmful than smoking, with risk estimates clustering in the 'at least 95% less harmful' range that Public Health England originally suggested in 2015 and that subsequent evidence has largely affirmed. The remaining uncertainty about long-term effects is real and should be acknowledged—but it should be weighed against the certainty about the effects of continued smoking. **The precautionary principle that demands certainty about vaping's safety while accepting the catastrophic certainty of smoking's danger is not a neutral application of caution. It is a systematic bias against the alternative that is keeping smokers alive.**
**The regulatory implications of the accumulated evidence are clear** but politically difficult. Products that are dramatically less harmful than cigarettes should be regulated proportionately to their risk—not subjected to the same restrictions as cigarettes, and not denied to smokers on precautionary grounds. The regulatory framework should create an incentive gradient that encourages smokers to switch to lower-risk products: lower taxes on lower-risk products, fewer marketing restrictions for products that serve a cessation function, and streamlined authorization pathways for products that are substantially equivalent to already-authorized devices. The communications framework should provide comparative risk information to smokers in clear, accessible language—acknowledging the remaining uncertainty while making clear that the risk differential between smoking and vaping is enormous. **The evidence is in. The policy is not. The gap between them is being measured in lives.**
**💬 Has the accumulating evidence on vaping changed your mind—or confirmed what you already believed?** If you were skeptical of vaping's harm reduction potential ten years ago, has the data shifted your view? If not, what evidence would it take?
